Biodesix Inc (BDSX) - Total Liabilities
Based on the latest financial reports, Biodesix Inc (BDSX) has total liabilities worth $86.18 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See BDSX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Biodesix Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Biodesix Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Biodesix Inc.
Biodesix Inc Competitors by Total Liabilities
The table below lists competitors of Biodesix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Intracom Holdings S.A.
AT:INTRK
|
Greece | €100.73 Million |
|
Oak Valley Bancorp
NASDAQ:OVLY
|
USA | $1.82 Billion |
|
KS Terminals Inc
TW:3003
|
Taiwan | NT$1.82 Billion |
|
Legato Merger Corp. III
NYSE MKT:LEGT
|
USA | $7.04 Million |
|
Molson Coors Canada Inc
TO:TPX-B
|
Canada | CA$13.95 Billion |
|
Saratoga Investment Corp
NYSE:SAR
|
USA | $818.97 Million |
|
Harvatek Corp
TW:6168
|
Taiwan | NT$653.70 Million |
|
Duopharma Biotech Bhd
KLSE:7148
|
Malaysia | RM689.10 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Biodesix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See BDSX net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 9.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.90 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biodesix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biodesix Inc (2018–2025)
The table below shows the annual total liabilities of Biodesix Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $89.94 Million | +17.77% |
| 2024-12-31 | $76.37 Million | -19.20% |
| 2023-12-31 | $94.52 Million | +30.73% |
| 2022-12-31 | $72.30 Million | +28.26% |
| 2021-12-31 | $56.37 Million | -29.45% |
| 2020-12-31 | $79.90 Million | -70.42% |
| 2019-12-31 | $270.17 Million | +13.95% |
| 2018-12-31 | $237.09 Million | -- |
About Biodesix Inc
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also pro… Read more